鱼跃医疗(002223) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥1,717,517,834.34, representing a year-on-year increase of 20.32%[3]. - Net profit attributable to shareholders was ¥388,857,313.73, showing a slight decrease of 0.52% compared to the same period last year[3]. - The net profit after deducting non-recurring gains and losses was ¥350,697,536.18, down 5.23% year-on-year[3]. - Total operating revenue for the third quarter reached ¥5,310,255,530.07, an increase of 9.5% compared to ¥4,848,208,229.63 in the same period last year[20]. - Net profit for the quarter was ¥1,352,256,432.42, a decrease of 10.2% from ¥1,506,829,260.41 in the previous year[21]. - Total comprehensive income for the third quarter was approximately CNY 1.35 billion, a decrease of 11% compared to CNY 1.51 billion in the same period last year[22]. - Basic and diluted earnings per share were CNY 1.3609, down from CNY 1.5065 year-over-year[22]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥12,214,918,282.48, an increase of 21.36% from the end of the previous year[3]. - The company's total assets reached CNY 12.21 billion, an increase from CNY 10.07 billion as of December 31, 2020, reflecting a growth of approximately 21.3%[16][17]. - The total liabilities reached ¥3,920,964,085.77, significantly higher than ¥2,570,350,399.36 from the previous year, indicating a growth of 52.5%[19]. - The company's total liabilities were CNY 2,570,350,399.36, while total equity stood at CNY 7,494,902,021.31[28]. - Current liabilities reached CNY 2,329,906,407.85, including short-term borrowings of CNY 640,507,222.22 and accounts payable of CNY 926,862,179.16[27]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥1,087,685,004.44, reflecting a significant decrease of 57.41% compared to the previous year[3]. - The net cash flow from operating activities decreased by 57.41% year-on-year, attributed to changes in sales policies and rising raw material prices[8]. - Cash inflow from operating activities totaled CNY 5.24 billion, down 10% from CNY 5.85 billion year-over-year[23]. - Cash outflow from operating activities increased to CNY 4.16 billion, compared to CNY 3.29 billion in the same period last year[24]. - Cash flow from investing activities resulted in a net outflow of approximately CNY 1.50 billion, an improvement from a net outflow of CNY 1.98 billion in the previous year[24]. - Cash flow from financing activities generated a net inflow of CNY 792 million, compared to CNY 91.94 million in the same period last year[24]. Acquisitions and Investments - The company completed the acquisition of Zhejiang Kailite Medical Equipment Co., Ltd., resulting in a 38.25% increase in goodwill[6]. - The company completed the acquisition of 50.993% equity in Zhejiang Kailite Medical Equipment Co., Ltd. for approximately CNY 365.94 million, with the transaction finalized on September 2, 2021[14][15]. - The company's advance receipts increased by 1216.96% compared to the beginning of the period, mainly due to the consolidation of Zhejiang Kailite Medical Equipment Co., Ltd.[7]. - The company plans to continue expanding its market presence and product offerings following the acquisition of Kailite, enhancing its competitive position in the medical equipment sector[14]. Expenses and Financial Metrics - Operating costs amounted to ¥3,882,930,768.81, up from ¥3,243,421,880.96, reflecting a year-over-year increase of 19.7%[20]. - Research and development expenses increased to ¥311,814,885.80, compared to ¥258,045,797.22, marking a rise of 20.9% year-over-year[20]. - The company's financial expenses decreased by 142.78% year-on-year, mainly due to foreign exchange gains from currency fluctuations[8]. - Other income increased by 53.30% year-on-year, primarily due to the recognition of government subsidies[8]. - The company's tax expenses increased by 39.16% year-on-year, driven by revenue growth and a higher proportion of domestic sales[7]. - The company's asset impairment losses increased by 474.29% year-on-year, primarily due to increased inventory write-downs during the reporting period[8]. Shareholder Information - The employee stock ownership plan involved the transfer of 6,622,216 shares at a price of CNY 22.50 per share, representing 0.66% of the company's total equity[14]. - The company's retained earnings reached CNY 4,138,172,321.89, contributing to total equity[28].